<DOC>
	<DOCNO>NCT00902954</DOCNO>
	<brief_summary>The purpose study compare rate disease free survival ( DFS ) distant disease free survival ( DDFS ) 5 year postmenopausal woman hormone receptor lymph node positive breast cancer randomize anastrozole/letrozole 5 year anastrozole/letrozole 2-3 year switch exemestane 3-2 year .</brief_summary>
	<brief_title>Study Exemestane After Anastrozole Letrozole Treatment Postmenopausal Women With Hormone Responsive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Provision write informed consent . 2 . Patient muse female . 3 . Patient must undergo primary breast cancer surgery institutional standard axillary dissection follow : A total mastectomy institutional standard axillary nodal dissection . Lumpectomy quadrantectomy institutional standard axillary dissection breast radiotherapy ( may defer chemotherapy complete ) accordance breast preservation . Treatment breast cancer follow diagnosis may include follow ; postlumpectomy/quadrantectomy regional radiotherapy , postmastectomy locoregional radiotherapy , postoperative chemotherapy , trastuzumab . 4 . The tumor must pathologic primary invasive carcinoma core needle open biopsy . 5 . The begin endocrine therapy ( letrozole anastrozole ) must 6 week end day chemotherapy radiotherapy . 6 . The date randomization must less 2 year letrozole 3 year letrozole treatment . 7 . Positive node define defined presence least micro metastasis great 0.2 mm accord AJCC Breast Staging Criteria Edition 6 . 8 . Patients neoadjuvant chemotherapy eligible . Positive lymph node involvement define either prior neoadjuvant chemotherapy time surgery follow neoadjuvant therapy . Lymph node positivity would define follow : Preneoadjuvant chemotherapy lymph node assessment must include identification histological positive axillary , internal mammary supraclavicular determine one following : FNA lymph node sentinel lymph node evaluation , complete limit axillary dissection . For patient complete neoadjuvant chemotherapy , without prior documentation positive lymph node , lymph node positivity must demonstrate time primary surgery define either : Either sentinel lymph node primary axillary dissection identify positive lymph node acceptable per standard institutional practice guideline . Histological evidence N1N3c lymph node involvement identify time primary breast surgery follow neoadjuvant chemotherapy . 9 . Presence occult axillary lymph node evidence primary breast tumor must confirm pathologically primary breast invasive carcinoma DCIS microinvasive . And measurement ER , PR HER2 must perform initial lymph node breast tumor . 10 . Bilateral , synchronous breast cancer allow provide least one primary tumor meet eligibility criterion . 11 . Hormone receptorpositive tumor , define detectable estrogen progesterone receptor expression institutional standards.Patients PR positive ER negative eligible trial . Tumor slide submit central evaluation hormone receptor status per Section . 12 . HER2 status must know , Tumor slide submitted central evaluation hormone receptor status per Section . 13 . Physical laboratory examination per standard institutional practice , obtain time definitive surgery demonstrate evidence metastatic recurrent disease . 14 . Patients must postmenopausal time initial diagnosis . For study purpose , postmenopausal define : Prior bilateral oophorectomy . Age ≥ 60 . Age &lt; 60 amenorrheic 12 month postmenopausal level FSH LH per local institutional standard If receive adjuvant chemotherapy tamoxifen age &lt; 60 , level FSH LH must reach postmenopausal level . If receive adjuvant chemotherapy LHRH antagonist amenorrheic , level FSH LH must reach postmenopausal level confirm least twice . 15 . Patients must WHO performance status perdisease performance without restriction , 1=restricted physically strenuous activity ambulatory . 16 . WBC &gt; 3.0*10^9/L platelet &gt; 100*10^9/L . 17 . AST/SGOT ALT/SGPT &lt; 3 time ULN . 18 . Cr ≤ 2 time ULN . 19 Can swallow pill . 1 . Presence metastatic disease . 2 . Previous diagnosis metachronous bilateral breast cancer . 3 . Previous concomitant ( nonbreast cancer ) malignance within previous 5 year except situ carcinoma cervix curatively treat basal squamous cell . 4 . Presence nonmalignant disease may prevent prolonged followup . 5 . Received neoadjuvant endocrine therapy . 6 . Adjuvant SERMs therapy ( Tamoxifen Toremifene ) 6 month randomization . 7 . Breast cancer chemoprevention antiestrogens less 18 month stop diagnosis breast cancer . 8 . Severe hepatic dysfunction define ChildPugh grade C. 9 . Severe cardiac dysfunction define NYHA grade III . 10 . Presence occult axillary lymph node evidence primary breast tumor pathologically DCIS microinvasive . And measurement ER , PR HER2 obtain . 11 . Uncontrolled psychological disease .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Disease free survival</keyword>
	<keyword>Distant disease free survival</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Overall survival</keyword>
</DOC>